Pharmacogenomics In Pharmacy Practice: Current Perspectives

References

• Shi MM, Bleavins MR, de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos. 2001;29(4 Pt 2):591–595.11259358
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.11237011
   PubMed Web of Science ®Google Scholar
• Feero WG, Guttmacher AE, Collins FS. Genomic medicine–an updated primer. N Engl J Med. 2010;362(21):2001–2011. doi:10.1056/NEJMra090717520505179
   PubMed Web of Science ®Google Scholar
• Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998;281(5384):1820–1821. doi:10.1126/science.281.5384.18209776686
   PubMed Web of Science ®Google Scholar
• Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–629. doi:10.1038/clpt.2011.18521900891
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.10523698643
   PubMed Web of Science ®Google Scholar
• FDA. Table of pharmacogenomic biomarkers in drug labeling. FDA. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm Published 2015 Accessed 123, 2015.
   Google Scholar
• Streetman DS. Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years. Ann Pharmacother. 2007;41(12):2038–2041. doi:10.1345/aph.1K27317956958
   PubMed Web of Science ®Google Scholar
• Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics. 2009;12(3):134–141. doi:10.1159/00018962519204415
   PubMed Web of Science ®Google Scholar
• Lee JW, Aminkeng F, Bhavsar AP, et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014;86(1):21–28. doi:10.1111/cge.2014.86.issue-124684508
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–458. doi:10.1038/clpt.2011.30622278335
   PubMed Web of Science ®Google Scholar
• Tamaoki M, Gushima H, Tsutani K. Awareness survey of parties involved in pharmacogenomics in Japan. Pharmacogenomics. 2007;8(3):275–286. doi:10.2217/14622416.8.3.27517324116
   PubMed Web of Science ®Google Scholar
• McMahon T, Tucci J. The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications. Pharm Pract (Granada). 2011;9(3):141–147.24367468
   PubMedGoogle Scholar
• Ratanajamit C, Kaewpibal P, Setthawacharavanich S, Faroongsarng D. Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs. J Med Assoc Thai. 2009;92(11):1500–1507.19938743
   PubMedGoogle Scholar
• Elewa HF, DeRemer CE, Keller K, Gujral J, Joshua TV. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis. 2014;38(1):115–120. doi:10.1007/s11239-013-0976-y23918529
   PubMed Web of Science ®Google Scholar
• Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014;34(10):1102–1112. doi:10.1002/phar.2014.34.issue-1025220280
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177. doi:10.1086/51039317173212
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013;33(11):1156–1164. doi:10.1002/phar.2013.33.issue-1123864527
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181–191. doi:10.1016/j.jcin.2017.07.02229102571
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet. 2014;166(1):76–84. doi:10.1002/ajmg.c.v166.1
   Web of Science ®Google Scholar
• Drozda K, Pacanowski MA, Grimstein C, Zineh I. Pharmacogenetic labeling of FDA-approved drugs: a regulatory retrospective. JACC Basic Transl Sci. 2018;3(4):545–549. doi:10.1016/j.jacbts.2018.06.00130175278
   PubMedGoogle Scholar
• Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013;14(7):835–843. doi:10.2217/pgs.13.5223651030
   PubMed Web of Science ®Google Scholar
• Gregory Feero W, Kuo GM, Jenkins JF, Rackover MA. Pharmacist education in the era of genomic medicine. J Am Pharm Assoc. 2012;52(5): e113-e121. doi:10.1331/JAPhA.2012.12149
   Google Scholar
• Swen J, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte— an update of guidelines. Clin Pharm Therapeut. 2011;89(5):662–673. doi:10.1038/clpt.2011.34
   PubMed Web of Science ®Google Scholar
• Hicks JK, Aquilante CL, Dunnenberger HM, et al. Precision pharmacotherapy: integrating pharmacogenomics into clinical pharmacy practice. JACCP. 2019;2(3):303–313.
   Google Scholar
• Zakinova A, Long-Boyle JR, French D, et al. A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service. JACCP. 2019;2(3):214–221.
   Google Scholar
• Owen JA. Integrating pharmacogenomics into pharmacy practice via medication therapy management: American Pharmacists Association. J Am Pharm Assoc. 2011;51(6):e64–e74. doi:10.1331/JAPhA.2011.11543
   Google Scholar
• Gervasini G, Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–774. doi:10.1007/s00228-010-0857-720582584
   PubMed Web of Science ®Google Scholar
• Relling M, Klein T. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharm Therapeut. 2011;89(3):464–467. doi:10.1038/clpt.2010.279
   PubMed Web of Science ®Google Scholar
• Haga SB, Moaddeb J, Mills R, Patel M, Kraus W, Allen LaPointe NM. Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics. 2015;16(17):1931–1941. doi:10.2217/pgs.15.12426555559
   PubMed Web of Science ®Google Scholar
• American Society of Health System Pharmacists. ASHP statement on the pharmacist’s role in clinical pharmacogenomics. Am J Health Syst Pharm. 2015;72(7):579–581. doi:10.2146/sp15000325788513
   PubMedGoogle Scholar
• Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011;78(4):243–257. doi:10.3949/ccjm.78a.1014521460130
   PubMed Web of Science ®Google Scholar
• Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39(5):1647–1652. doi:10.1161/STROKEAHA.107.18906318322260
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420. doi:10.1001/jama.288.19.241112435254
   PubMed Web of Science ®Google Scholar
• Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease–implications for personalized medicine. Pharmacol Rev. 2013;65(3):987–1009. doi:10.1124/pr.112.00725223686351
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20(7):463–465. doi:10.1097/FPC.0b013e328338542020440227
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92–99. doi:10.1124/dmd.109.02913219812348
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–317. doi:10.1016/S0140-6736(08)61845-019108880
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362. doi:10.1056/NEJMoa080917119106084
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375. doi:10.1056/NEJMoa080822719106083
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010;8(8):1678–1684. doi:10.1111/j.1538-7836.2010.03923.x20492467
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857. doi:10.1001/jama.2009.123219706858
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. ‎U.S. Food and Drug Administration. Published 2010 Accessed 2016.
   Google Scholar
• Paravattil B, Elewa H. Strategies to optimize dual antiplatelet therapy after coronary artery stenting in acute coronary syndrome. J Cardiovasc Pharmacol Ther. 2017;22(4):347–355. doi:10.1177/107424841668304828587584
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47. doi:10.1038/nrcardio.2014.15625286881
   PubMed Web of Science ®Google Scholar
• Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother. 2011;12(8):1285–1295. doi:10.1517/14656566.2011.55057321254864
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Ruiz-Nodar JM, Orenes-Pinero E, et al. Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes. J Cardiovasc Pharmacol Ther. 2017;1074248417724869.
   Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi:10.1056/NEJMoa070648217982182
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/NEJMoa090432719717846
   PubMed Web of Science ®Google Scholar
• Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial. J Am Coll Cardiol. 2018;71(17):1869–1877. doi:10.1016/j.jacc.2018.02.02929540324
   PubMed Web of Science ®Google Scholar
• Jiang M, You JH. Cost–effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics. 2016;17(7):701–713. doi:10.2217/pgs-2016-000827167099
   PubMed Web of Science ®Google Scholar
• Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160(4):221–232. doi:10.7326/M13-199924727840
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Roberts D, Pirmohamed M, Hughes DA. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016;34(8):771–793. doi:10.1007/s40273-016-0397-926984520
   PubMed Web of Science ®Google Scholar
• Wang Y, Yan B, Liew D, Lee V. Cost-effectiveness of cytochrome P450 2C19* 2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenomics J. 2018;18(1):113. doi:10.1038/tpj.2016.9428117433
   PubMed Web of Science ®Google Scholar
• Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01742117 Published 2012 Updated October 30, 2018 Accessed 2019.
   Google Scholar
• Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01761786 Published 2013 Updated April 17, 2018 Accessed 2019.
   Google Scholar
• Elewa H, Ahmed D, Barnes GD. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting: searching for the best combination. Semin Thromb Hemost. 2016 Sep;42(6):662–670.
   Google Scholar
• Gong X, Gutala R, Jaiswal AK. Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85–101.18374191
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Marinova M, Muller-Reible C, Watzka M. The vitamin K cycle. Vitam Horm. 2008;78:35–62.18374189
   PubMed Web of Science ®Google Scholar
• Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015;8(2):171–175.25866574
   PubMedGoogle Scholar
• Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology. Berline, Heidelberg: Springer; 2008:109–111.
   Google Scholar
• Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315–328. doi:10.1016/0002-9343(93)90285-W8368229
   PubMed Web of Science ®Google Scholar
• Nunnelee JD. Review of an article: the International Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753–64. J Vasc Nurs. 2009;27(4):109. doi:10.1016/j.jvn.2009.09.00119914573
   PubMedGoogle Scholar
• Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75(3):204–212. doi:10.1016/j.clpt.2003.10.00115001972
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121(1):23–34. doi:10.1007/s00439-006-0260-817048007
   PubMed Web of Science ®Google Scholar
• Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14(13):1745–1751. doi:10.1093/hmg/ddi18015888487
   PubMed Web of Science ®Google Scholar
• Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011;21(3):130–135. doi:10.1097/FPC.0b013e3283436b8621228733
   PubMed Web of Science ®Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433. doi:10.1371/journal.pgen.100043319300499
   PubMed Web of Science ®Google Scholar
• Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25(1):45–51. doi:10.1007/s11239-007-0104-y17906972
   PubMed Web of Science ®Google Scholar
• Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115(18):3827–3834. doi:10.1182/blood-2009-12-25599220203262
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293. doi:10.1056/NEJMoa131066924251361
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–2303. doi:10.1056/NEJMoa131138624251363
   PubMed Web of Science ®Google Scholar
• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41. doi:10.1016/j.tcm.2014.09.00125282448
   PubMed Web of Science ®Google Scholar
• Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–1124. doi:10.1001/jama.2017.1146928973620
   PubMed Web of Science ®Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update. Clin Pharm Therapeut. 2017;102(3):397–404. doi:10.1002/cpt.668
   PubMed Web of Science ®Google Scholar
• Bank P, Caudle K, Swen J, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the Dutch Pharmacogenetics Working Group. Clin Pharm Therapeut. 2018;103(4):599–618. doi:10.1002/cpt.v103.4
   PubMed Web of Science ®Google Scholar
• ASHP. ASHP statement on the pharmacist’s role in clinical pharmacogenomics. ASHP statement Web site. Available from: http://www.ashp.org/DocLibrary/Policy/HOD/StPharmacogenomicsPrepress.aspx Published 2014 Accessed 117, 2015.
   Google Scholar
• Caudle KE, Gammal RS, Karnes JH, et al. PRN OPINION PAPER: application of precision medicine across pharmacy specialty areas. J Am Coll Clin Pharm. 2019;2(3):288–302. doi:10.1002/jac5.2019.2.issue-3
   Google Scholar